ALZ-1903

ALZ-1903 is a small molecule drug developed by Alzheon. It acts as an inhibitor of amyloid beta (Aβ) misfolding and aggregation, targeting the amyloid precursor protein (APP). The drug is classified as a neuroprotectant and is designed to modulate beta amyloid A4 protein, aiming to prevent or reduce the formation of toxic amyloid aggregates implicated in neurodegenerative diseases. Its primary indications under investigation have included dry age-related macular degeneration, inclusion body myositis, and amyloidosis. As of the latest updates, development has not advanced beyond preclinical stages for these conditions[1][2].